| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692568 | European Urology | 2016 | 4 Pages |
Abstract
The combination of hormonal therapy and chemotherapy may improve outcomes in men with metastatic prostate cancer. This study demonstrates the ability to combine the hormonal therapy agent abiraterone acetate, plus prednisone, and the chemotherapy drug docetaxel with an acceptable side effect profile. A high rate of prostate-specific antigen decline was seen, but the study was small and additional research is needed before this becomes a standard approach.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Scott T. Tagawa, Edwin M. Posadas, Justine Bruce, Emerson A. Lim, Daniel P. Petrylak, Weimin Peng, Thian Kheoh, Scott Maul, Johan W. Smit, Martha D. Gonzalez, Peter De Porre, NamPhuong Tran, David M. Nanus,